Bloomberg News reports, “US regulators may warn patients taking tamoxifen, a breast cancer medicine…not to use certain types of antidepressants because they block the tumor-fighting drug’s effectiveness.” According to Karen Riley, a spokeswoman for the FDA, the agency is considering “‘adding new information to the tamoxifen label’ to advise women taking the cancer drug against using some antidepressants.” The move follows new evidence, presented a study May 30 at the meeting of the American Society of Clinical Oncology, that “tumors were more than twice as likely to return after two years in women taking the antidepressants while on the cancer drug, compared with those taking tamoxifen alone.”
From the American Association for Justice news release.
